Sumatriptan Succinate Tablet, Film Coated
Product Images NDC 71205-274

4 FDA label images from Proficient Rx Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 71205-274). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of sumatriptan succinate, depicting the molecular components including the indole core with attached sulfonamide and amine groups, and the succinate moiety.*
FDA Label Image

71205-274-09 (Sumatriptan Carton 100mg)

71205-274-09 (Sumatriptan Carton 100mg)
Label for sumatriptan succinate 100 mg film-coated tablets by Proficient Rx LP, featuring a pink, triangular tablet description debossed with "S" and "100." The label includes product ID SS027409, manufacturer details (Sun Pharmaceutical Industries Ltd., India), storage instructions, and multiple smaller copies of the main label with batch and expiration placeholders.*
FDA Label Image

Sumatriptan-figure-1 (Sumatriptan Figure 1)

Sumatriptan-figure-1 (Sumatriptan Figure 1)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 4 hours after treatment with oral sumatriptan in pooled clinical trials. The graph compares placebo, 25 mg, 50 mg, and 100 mg doses over time from 0 to 240 minutes, illustrating increasing response probabilities with higher doses.*
FDA Label Image

Sumatriptan-figure-2 (Sumatriptan Figure 2)

Sumatriptan-figure-2 (Sumatriptan Figure 2)
A Kaplan-Meier plot showing the estimated probability of patients taking a second dose of sumatriptan succinate tablets or other medication to treat migraine over 24 hours following the initial dose. The plot compares placebo and sumatriptan succinate doses of 25 mg, 50 mg, and 100 mg, illustrating the probability of remediation or rescue treatment over time in hours from the initial dose.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.